Resources
22 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 4/21/2021 (updated 4/5/2024)
This News Brief describes the need for harm reduction and treatment services in rural areas for people who use psychostimulants and how those services can be provided by the opioid treatment program
Posted 3/25/2021 (updated 4/5/2024)
Care Coordination: Navigating Individuals With OUD Through a Treatment and Recovery Continuum
Presenters from the Western Region will describe two innovative care coordination strategies and models from the RCORP/Rural Health Opioid Program grantee perspective.
Posted 3/5/2021 (updated 4/5/2024)
The United States is facing a crisis of opioid-related overdose. At this time, more people die of overdose every year than died of AIDS at the peak of the HIV epidemic. Communities seek effective responses to prevent opioid death.
Posted 11/18/2020 (updated 4/3/2024)
Pharmacists can play an important role in improving access to medication for opioid use disorder (MOUD), especially for individuals living in rural areas where health care workforce shortages are pervasive. Learn how pharmacists can provide Medication Administration Services (MAS) and establish Collaborative Practice Agreements (CPA) in coordination with one or more treating health care providers.
Posted 8/19/2021 (updated 4/2/2024)
In spring 2021, pharmaceutical manufacturers and distributors notified syringe services programs (SSPs) and partners that there would be significant interruptions in the supply of injectable/intramuscular (IM) naloxone. Currently, production and distribution delays are expected to last until fall 2021. This will specifically affect SSPs because IM naloxone is the most affordable formulation, and therefore is most commonly utilized by programs that distribute large volumes of naloxone to reduce fatal overdose rates.
Posted 7/28/2021 (updated 4/2/2024)
The most effective treatments for opioid use disorder (OUD) are the three prescription medications approved by the U.S. Food and Drug Administration (FDA)—methadone, buprenorphine, and naltrexone—that are proved to increase a patient’s treatment retention and reduce illicit use and the risk of overdose. The only facilities legally able to offer all three medications are opioid treatment programs (OTPs), a critical component of the U.S. substance use treatment system that are regulated by the federal Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA), as well as state agencies, and are certified to administer any FDA-approved medication for the treatment of OUD.
Posted 7/19/2021 (updated 4/2/2024)
Buprenorphine/naloxone, an evidence-based treatment for opioid use disorder, is sometimes diverted for non-medical use. In Rhode Island, the prevalence of opioid use and, more recently, of fentanyl in the illicit drug supply is driving overdose fatalities, which increases the need for treatment and raises questions about the changing role of diverted medication in shaping overdose risk.
Posted 1/24/2020 (updated 3/28/2024)
Get Naloxone Now is an online resource to train people to respond effectively to an opioid overdose emergency.
Posted 1/22/2020 (updated 3/28/2024)
With opioid deaths on the rise and fentanyl deaths rapidly increasing, a crisis of this magnitude requires innovative responses at multiple intervention points, including post-overdose, as part of a comprehensive strategy to aid in the treatment of and recovery from opioid use disorders. This article explores law enforcement overdose reversal and post-resuscitation and treatment responses in the newly emerging field of pre-arrest diversion.
Posted 11/21/2019 (updated 3/28/2024)
This is a briefing for law enforcement personnel around the world on how to incorporate, support, and create space for approaches that aim to increase public safety and health, reduce harm to people who use drugs, and provide law enforcement alternatives to common punitive models.